Lantern Pharma (NASDAQ: LTRN), an AI-driven precision oncology company, announced that the United States Patent and Trademark Office issued a Notice of Allowance for U.S. Patent Application No. 18/500,032, covering methods of using LP-284 to treat mantle cell lymphoma (MCL), double-hit lymphoma (DHL), and other blood cancers. The allowed claims include LP-284 as a monotherapy and in combination with several classes of anti-cancer agents. Once issued, the patent is expected to extend LP-284 intellectual property protection into 2042, adding method-of-use protection to Lantern's existing composition-of-matter patent estate. This development matters because it could solidify Lantern's competitive position in the blood cancer treatment market, where effective therapies for relapsed or refractory cases remain limited.
LP-284 is currently being evaluated in an ongoing Phase 1a dose-escalation clinical trial in patients with relapsed or refractory B-cell non-Hodgkin lymphoma and solid tumors. The drug was developed through the company's RADR artificial intelligence platform, which integrates large-scale genomic and biological data with machine learning to identify patients most likely to benefit from its therapies and to guide biomarker-driven clinical development. LP-284 has received three FDA Orphan Drug Designations, including for MCL, high-grade B-cell lymphoma with MYC and BCL2 rearrangements, and soft tissue sarcomas. For investors, the patent allowance may enhance the long-term value of Lantern's pipeline by potentially delaying generic competition and supporting premium pricing if the drug reaches market.
Lantern Pharma is a clinical-stage biopharmaceutical company leveraging its proprietary RADR platform to transform the cost, pace, and precision of oncology drug development. Its pipeline includes LP-184 (zirdafulven), LP-300, and LP-284, along with its central-nervous-system-focused subsidiary, Starlight Therapeutics, and its AI subsidiary, Open-Medicine AI. The latest news and updates relating to LTRN are available in the company's newsroom at https://ibn.fm/LTRN. To view the full press release, visit https://ibn.fm/5zEya.
MissionIR, a specialized communications platform focused on assisting IR firms with syndicated content to enhance the visibility of private and public companies, distributed the announcement. It is one of 75+ brands within the Dynamic Brand Portfolio at IBN that delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics, and diverse industries; article and editorial syndication to 5,000+ outlets; enhanced press release enhancement to ensure maximum impact; social media distribution via IBN to millions of social media followers; and a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. For more information, please visit MissionIR. Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer.
